Steroids, Hyaluronic Acid or Platelet Rich Plasma Versus Placebo for the Knee Osteoarthritis

Intraarticular Injections of Steroids, Hyaluronic Acid or Platelet Rich Plasma Versus Placebo for the Knee Osteoarthritis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02776514

Acronym

KIT

Enrollment

120

Registered

2016-05-18

Start date

2016-02-29

Completion date

2020-11-30

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee

Brief summary

This study investigates clinical outcome and imaging outcome parameters after intraarticular injection of steroids, platelet-rich-plasma (prp), hyaluronic acid or placebo in patients with early osteoarthritis of the knee joint.

Detailed description

Osteoarthritis of the knee joint is a very common disease in middle aged and elderly patients. This study evaluates the efficiency of different commonly used substances for intraarticular, non-operative treatment in early stages of this disease. 120 patients receive an fluoroscopic guided injection in the knee joint: 30 patients get injection with steroids 30 patients get injection with prp 30 patients get injection with hyaluronic acid 30 patients get injection with placebo (iopamiro contrast media) Primary outcome: - clinical outcome (pain using numeric rating scale) * Magnetic Resonance imaging (cartilage defects etc.)

Interventions

DRUGTriamcort

Fluoroscopic guided injection in the knee joint

DRUGPlatelet-rich-plasma

DRUGSuplasyn1

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* gonarthritis Kellgren 1,2,3 with symptoms * german speaking * informed consent

Exclusion criteria

-age under 18, gonarthritis, Kellgren 4, anticoagulation therapy, known inflammatory disease or infection, cardiovascular disease NYHA IV, immunosuppression, contraindication for MRI, pregnancy, no informed consent, NSAR 3 days before injection, etc.

Design outcomes

Primary

Measure	Time frame	Description
Pain assessment	up to 24 months after injection	numeric rating scale (NRS) and WOMAC
Magnetic Resonance imaging	up to 12 months after injection	cartilage volume (ml)

Secondary

Measure	Time frame	Description
WOMAC score (stiffness, difficulty)	up to 24 months after injection	Clinical outcome
Tegner Activity Scale	up to 24 months after injection	Clinical outcome
Knee mobility and thigh circumference	3 month after injection	Clinical assessment, comparison to baseline

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026